Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
10 evidence topics · 10 sources
Office blood pressure measurement: standardized protocol
Out-of-office blood pressure: home and ambulatory monitoring
Pseudoresistance: confirmation of true treatment resistance
“Assessment for treatment adherence and use of ABPM (or home BP monitoring if ABPM is unavailable) are needed to confirm RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaccurate measurement of BP can result in the appearance of treatment resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this study of patients referred for RH, inaccurate BP measurement was estimated at 33%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
White-coat effect in apparent treatment-resistant hypertension
“A clinically significant white-coat effect may be present in 28% to 39% of individuals with aTRH by office BP measurement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among them, 8295 (12.2% of the database) had resistant hypertension (office blood pressure ≥140 and/or 90 mm Hg while being treated with ≥3 antihypertensive drugs, 1 of them being a diuretic).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After ambulatory blood pressure monitoring, 62.5% of patients were classified as true resistant hypertensives, the remaining 37.5% having white-coat resistance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medication nonadherence: prevalence and adherence testing
“From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“the pooled prevalence of nonadherence was 31.2%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“with nonadherence rates ranging from 3.3 to 86.1%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The strongest contributor to variance in nonadherence rates was the method of adherence assessment used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There is no gold standard for measuring adherence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A direct method such as urine or blood measurement of drug or metabolites is considered more robust but is relatively expensive, is of limited availability, and does not perfectly reflect level of adherence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary aldosteronism screening: 2025 Endocrine Society guideline
“We suggest that all individuals with hypertension be screened for PA by measuring aldosterone and renin and determining the aldosterone to renin ratio, and that subsequent clinical care be guided by the results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“the 2025 Endocrine Society guideline extends screening recommendations beyond high-risk subgroups to encompass all adults with hypertension, issuing a conditional (Grade 2) recommendation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Specifically, a positive screen is defined by a suppressed renin – plasma renin activity (PRA) ≤1 ng/mL/h or direct renin concentration (DRC) ≤8.2 mU/L – in combination with inappropriately elevated aldosterone (≥10 ng/dL by immunoassay or ≥7.5 ng/dL by liquid chromatography), and an elevated ARR (aldosterone [ng/dL] to PRA [ng/mL/h] ratio >20 or aldosterone [pmol/L] to DRC [mU/L] ratio >70).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote